didnt manage to scalp and trade the Moderna stock. what a waste. but well, it is still a good news for holders and the world
Moderna had its best day ever Wednesday: shares soared 177% after its melanoma vaccine, developed with Merck, became the first mRNA cancer therapy to succeed in a Phase 3 trial. Merck rose alongside i...



